The Technical Analyst
NovAccess Global Inc. [XSNX]
Exchange: PNK Industry: Biotechnology
NovAccess Global Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0065
America/New_York / 3 mai 2024 @ 14:32
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.180 mill |
| EPS: | -0.0800 |
| P/E: | -0.0800 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 27.67 mill |
| Avg Daily Volume: | 0.505 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0800 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0800 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0035 - 0.0095 ( +/- 46.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-13 | Laird Neil J | Buy | 428 571 | Stock Option (right to buy) |
| 2023-03-13 | Cassarini John | Buy | 857 143 | Stock Option (right to buy) |
| 2023-03-13 | Anderson Jason Michael | Buy | 857 143 | Stock Option (right to buy) |
| 2022-03-18 | Anderson Jason Michael | Sell | 0 | Common Stock, no par value |
| 2022-03-14 | Cassarini John | Sell | 0 | Common Stock, no par value |
| INSIDER POWER |
|---|
| 100.00 |
| Last 40 transactions |
| Buy: 14 956 127 | Sell: 5 041 000 |
Forecast:
16:00 - $0.0065
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0065 (0.00% ) |
| Volume | 0.0855 mill |
| Avg. Vol. | 0.505 mill |
| % of Avg. Vol | 16.92 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XSNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XSNX
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.
Latest Press Releases
2024-04-30 09:00:00 - Press Release
Novaccess Global Announces New License To Advance Its Immunotherapy Platform
Cleveland, oh / accesswire / april 30, 2024 / novaccess global inc. (otcqb:xsnx), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from cedars-sinai medical center to further advance the company's immunotherapy platform. the license pertains to the use of isocitrate dehydrogenase-1 (idh1), a protein previously known to impact cell metabolism.
2024-03-01 09:00:00 - Press Release
Novaccess Global Provides Business Updates And Announces Scheduling Of Annual Meeting Of Shareholders
Cleveland, oh / accesswire / march 1, 2024 / novaccess global inc. (otcqb:xsnx), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. the previously disclosed $10.7 million financing transaction with sumner global llc remains pending, as sumner global has not yet obtained the funding necessary to close the transaction.
2024-01-02 08:00:00 - Press Release
Novaccess Global Announces $10.7 Million Financing
Establishes strong financial base to advance development of novel cancer immunotherapies cleveland, oh / accesswire / january 2, 2024 / novaccess global inc. (otcqb:xsnx), a biomedical company developing novel immunotherapies for brain tumor patients, today announced it entered into a securities purchase agreement with an affiliate of sumner global llc ("sumner") for a total financing of $10.7 million. pursuant to the agreement, sumner agreed to purchase 33.0 million newly issued shares of the company's unregistered common stock at $0.11 per share, for a $3.63 million cash investment payable on or before january 31, 2024, subject to a financing contingency.
2023-12-01 16:51:00 - Press Release
Novaccess Global Inc. To Present At The December 7th Virtual Investor Summit
Cleveland, ohio--(newsfile corp. - december 1, 2023) - novaccess global inc. (otcqb: xsnx) announced today it will be presenting at the december 7th, 2023 virtual investor summit. event: december 7th investor summit presentation: december 7th, 2023 @ 1:30 pm et location: https://us06web.zoom.us/webinar/register/wn_ps0tlsybtuyu5q9_j_oxya 1x1s will be available for qualified investors the conference is completely complimentary to qualified investors about novaccess global novaccess global is a preclinical, ind-ready biomedical company accelerating novel cancer diagnostics and therapeutics.
2023-11-10 09:00:00 - Press Release
Novaccess Global Appoints Dr. Roscoe M. Moore, Jr. To Scientific Advisory Board
Cleveland, oh / accesswire / november 10, 2023 / novaccess global inc. (otcqb:xsnx), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of dr. roscoe m. moore, jr., to its scientific advisory board.
Latest News
2023-12-01 16:51:00 - Newsfile Corp
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. Event: December 7th Investor Summit Presentation: December 7th, 2023 @ 1:30 PM ET Location: https://us06web.zoom.us/webinar/register/WN_ps0tLsybTUyu5q9_J_OXYA 1x1s will be available for qualified investors The conference is completely complimentary to qualified investors About NovAccess Global NovAccess Global is a preclinical, IND-ready biomedical company accelerating novel cancer diagnostics and therapeutics.
2023-02-16 09:00:00 - Accesswire
NovAccess Global to Present at World Orphan Drug Congress
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan Drug Congress, scheduled for May 23-25, 2023, near Washington, DC. Dr. Christopher Wheeler, Ph.D.
2023-02-03 09:00:00 - Accesswire
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his Contributions CLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin and Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company, will be presenting at the World Brain Mapping Foundation Annual Congress, scheduled to be held on Friday, February 17, 2023, in Los Angeles, CA.